FDA spanks KVK Tech over impurities in ADHD drug

The FDA has found impurities testing at U.S. generics maker KVK Tech were insufficient. (Image by PublicDomainPictures from Pixabay)

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with an ADHD drug as well as one for weight loss. 

The FDA, in a warning letter posted this week, says, among other problems, KVK Tech of Newtown, Pennsylvania, failed to properly integrate co-eluting peaks during impurity testing of its phentermine HCL capsules, a drug used for weight loss. As a result, the letter says the analysis failed to detect out-of-specification results for at least one lot of the drug.

KVK Tech said even though its methods might underestimate impurities in the drug, the impact was minimal because “the failing batches were ultimately recalled from the market, albeit at a potentially later time.” 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: Generic drugmaker snaps up Lockheed site with big expansion plans

The FDA, unimpressed by this argument, ordered the company to bring in an independent consultant to help it assess its laboratory practices and then put together a plan on how it intends to bring them up to agency expectations. 

The letter also found problems with the plant’s investigation of foreign particles found in a lot of the ADHD drug methylphenidate oral solution. The company said the particles were introduced during filling by wipes used in cleaning equipment. But the FDA said KVK Tech had not adequately investigated the particles and their potential effect on the drug’s quality before releasing the lot. 

In addition to providing the agency with a thorough assessment of how it investigates deviations, the FDA asked for an independent assessment of four years worth of manufacturing records “to determine if manufacturing events” that should have been uncovered had been missed. 

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.